NeuroPace (NPCE) investor relations material

Company overview and mission

• Focused on transforming the lives of patients with debilitating seizures, leveraging a mix of experienced leadership and new talent to drive growth and operational expansion.

• Achieved $100 million in revenue in 2025, growing at 25%, with over 8,000 patients treated and increasing market penetration and account presence.

• Targets the 1.2 million drug-resistant epilepsy patients in the U.S., with a significant total addressable market (TAM) and plans to expand beyond Level 4 epilepsy centers.

• Demonstrated over 20% growth in recent years, with confidence in continued expansion through indication growth and best-in-class technology.

Clinical and product development

• Submitted a PMA supplement to the FDA for indication expansion into idiopathic generalized epilepsy (IGE), with potential approval expected mid-2026.

• Developing clinical programs for pediatric focal and Lennox-Gastaut patients, and exploring applications beyond epilepsy.

• Launched AI and machine learning tools to enhance seizure detection and therapy settings, aiming to improve device usability and clinician efficiency.

• Advanced remote programming capabilities to increase patient accessibility.

Financial performance and guidance

• 2025 revenue of $100 million included discontinued SEEG DIXI business; 2026 guidance is $98–$100 million for the core RNS business, reflecting 20–22% growth.

• Exited the SEEG DIXI business to improve gross margins, which have increased significantly.

• Adjusted EBITDA introduced as a proxy for cash generation, with strong gross margins expected to continue.